Analiza launches non-invasive cardiology unit at Hospital HLA Moncloa

Analiza launches non-invasive cardiology unit at Hospital HLA Moncloa

Creation and start-up of Non-Invasive Cardiology Unit to allow for coordination between screening and clinical departments.


Early detection and early treatment are essential for people with CVD or high cardiovascular risk.

With the start-up of the Non-Invasive Cardiology Unit at the HLA Moncloa University Hospital, Analiza has further implemented its strategic plan to provide end-to-end screening. This new unit includes advanced cardiovascular imaging techniques and standalone units that put test results into context and pave the way for personalised medicine.


The coordination between the screening department and the clinical department is one of the most groundbreaking features of this new division, as the same person will perform the tests and see the patient for appointments. This will allow for early detection and early treatment of cardiovascular diseases (CVD), which are the leading cause of death worldwide.


Continuing with its commitment to innovation and investment into state-of-the-art technology, Analiza has decided on the use of Cardiac CT in the planning of cardiovascular surgical procedures, particularly for the implantation of percutaneous prostheses or prior to electrophysiological studies of pulmonary vein isolation in patients with atrial fibrillation. Meanwhile, Cardiac MRI is the test of choice for studying myocardial diseases and assessing damage after an acute myocardial infarction.  One of the standout elements compared to other units is that not only will all screening techniques be available, but also they will be linked to the valvulopathy unit and the inherited heart disease unit (focused on myocardial diseases). The coordination between these units and the cardiovascular imaging unit guarantees the individualisation of the diagnosis and the personalised treatment of patients with cardiovascular diseases.


The cardio scanning division is directed by Dr Jorge Solís, Bachelor in Medicine with specialisation in Cardiology from the Complutense University of Madrid. He gained his extensive experience in cardiovascular research in the USA, always focusing on cardiovascular imaging and valvular pathology. Dr Solis continued his training for four years at the echocardiography laboratory of Massachusetts General Hospital (Harvard Medical School, Boston), where he focused his scientific activity on the development of three-dimensional echocardiography and new therapies in mitral regurgitation, being nominated for an Early Career Investigator Award by the American Heart Association and American Society of Echocardiography (2007, 2008). He is the chief researcher of the scientific network established through the PROMESA study (study of mitral prolapse at Spanish hospitals), in collaboration with the mitral valve group of the Leducq Foundation for the study of this condition. Thanks to this collaboration, the genetic bases of mitral valve prolapse have been established (published in Nature, Nature Genetic and Nature Cardiovascular Review in 2015).

¿Quieres recibir noticias como ésta en tu email?

Suscríbete a la newsletter